Details of the Drug Combinations

General Information of This Drug (ID: DML6HP3)

Drug Name

HSP-990 DML6HP3

Synonyms

NVP-HSP990; 934343-74-5; HSP-990; UNII-E0WBA7B62L; HSP990 (NVP-HSP990); E0WBA7B62L; HSP990; NVP-HSP990(HSP990); SCHEMBL1351184; CHEMBL3360305; (7r)-2-Amino-7-[4-Fluoro-2-(6-Methoxypyridin-2-Yl)phenyl]-4-Methyl-7,8-Dihydropyrido[4,3-D]pyrimidin-5(6h)-One; NVP-HSP-990; HSP990 (NVP-HSP); NVP-HSP990,HSP990; DTXSID50239429; MolPort-023-219-119; 4u93; HSP990, NVP-HSP990; EX-A1560; AOB87737; NVP-HSP990 (HSP990); ZINC60329723; 2608AH; s7097; BDBM50031735; AKOS025404948; CS-3941; SB16642; BCP9001013

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
HSP-990 + Panobinostat	DC9ACUK	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00879905) A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.